Xagrid (anagrelide)
- Region
- 🇪🇺 EU
- Active substance
- anagrelide
- Company
- Takeda Pharmaceuticals International AG Ireland
- Status
- Authorised
- Therapeutic area
- Thrombocythemia, Essential
- EU approval
- Mon 15 Nov 2004
- Application
- EMEA/H/C/000480
- ATC
- L01XX35
- Official record
- www.ema.europa.eu
Indication
Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk ET is defined by one or more of the following features: >60 years of age or; a platelet count >1000 x 109/l or; a history of thrombohaemorrhagic events.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Anagrelide Viatris (previously Anagrelide Mylan) Authorised · Viatris Limited
Follow Xagrid
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.